Insta
Johnson & Johnson Temporarily Pauses Covid-19 Vaccine Trials Due To 'Unexplained' Illness In Study Participant
Covid-19 vaccine - representative image (Twitter)
Pharma major Johnson & Johnson on Monday (12 October) said that it has temporarily paused the the clinical trials of its Covid-19 vaccine candidate due to an "unexplained illness" in a study participant.
The decision regarding resumption of the trials will be taken after careful review of the medical information, the company said.
"We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," Johnson & Johnson said in a press release.
"Following our guidelines, the participant’s illness is being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board (DSMB) as well as our internal clinical and safety physicians," it added.
Adverse events – illnesses, accidents, etc. - even those that are serious, are an expected part of any clinical study, especially large studies, the company said.
It should be noted that earlier in September, British-Swedish pharma company AstraZeneca had also halted the clinical trials of its Covid-19 vaccine candidate following a serious adverse event. However, the trials were later resumed after the Medicines Health Regulatory Authority (MHRA) of United Kingdom confirmed that it was safe to do so.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
